A brave nine-year-old boy tackling a rare type of cancer has raised over £1,590 for Birmingham Children’s Hospital Charity ...

(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of ...

“Although shareholder rights plans are generally viewed with caution by investors and Glass Lewis, particularly in the context of public shareholder dissent, the facts of this case do not, in our view ...

With its existing entitlement, plus the newly acquired economics from BioInvent, XOMA Royalty will be entitled to milestones ...

A new combination therapy that pairs a radiopharmaceutical (177Lu-DOTATATE) with a DNA-repair blocker (olaparib) has been ...

Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple ...

In a recent study, a research team led by Professor Hyun Hye-kyung and Professor Heo Cheol-woong of Yonsei University's ...

A new study identifies eight domains of active systemic #lupus erythematosus for defining meaningful treatment response in ...

West Virginia Department of Health and Human Resources and the Bureau for Public Health reports that while Lyme Disease ...

Amplia Therapeutics is making strides with its candidate that works on the anti-fibrotic path to tackling pancreatic cancer.

EMA’s human medicine committee recommends approval of GSK’s Blenrep combinations in relapsed/refractory multiple myeloma: London, UK Monday, May 26, 2025, 10:00 Hrs [IST] GSK ...

Results of a randomized, placebo-controlled study demonstrated avatrombopag achieved the primary endpoint of platelet response in heavily pretreated pediatric patients with persistent or chronic ITP.